Bank Of America Corp Innate Pharma Sa Transaction History

Bank Of America Corp

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	SELL	$2.67 - $3.86 $291,142 - $420,902	-109,042 Reduced 69.99%	46,749 $133,000
Q4 2022 Feb 10, 2023	SELL	$1.9 - $3.73 $17,075 - $33,521	-8,987 Reduced 5.45%	155,791 $581,000
Q3 2022 Nov 14, 2022	SELL	$2.0 - $3.2 $20,902 - $33,443	-10,451 Reduced 5.96%	164,778 $330,000
Q2 2022 Aug 12, 2022	BUY	$2.0 - $3.55 $90 - $159	45 Added 0.03%	175,229 $473,000
Q1 2022 May 16, 2022	SELL	$2.7 - $4.8 $194,040 - $344,961	-71,867 Reduced 29.09%	175,184 $589,000
Q4 2021 Feb 08, 2022	BUY	$4.34 - $6.06 $316,607 - $442,083	72,951 Added 41.9%	247,051 $1.13 Million
Q3 2021 Nov 15, 2021	BUY	$3.04 - $8.1 $529,264 - $1.41 Million	174,100 New	174,100 $1.07 Million

238K

Ticker IPHA
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 79,893,000
Market Cap $141M
Description
Innate Pharma S.A., a biotechnology company, discovers, develops, and commercializes therapeutic antibodies for the treatment of oncology indications in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and periphera...

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

Stay updated on Bank Of America Corp with notifications on news.